

**Non-opposition to a notified concentration****(Case COMP/M.2192 — Smithkline Beecham/Block Drug)**

(2001/C 43/06)

**(Text with EEA relevance)**

On 11 January 2001 the Commission decided not to oppose the above notified concentration and to declare it compatible with the common market. This decision is based on Article 6(1)(b) of Council Regulation (EEC) No 4064/89. The full text of the decision is only available in English and will be made public after it is cleared of any business secrets it may contain. It will be available:

- as a paper version through the sales offices of the Office for Official Publications of the European Communities (see list on the last page),
- in electronic form in the 'CEN' version of the CELEX database, under document No 301M2192. CELEX is the computerised documentation system of European Community law.

For more information concerning subscriptions please contact:

EUR-OP,  
Information, Marketing and Public Relations (OP/A/4-B),  
2, rue Mercier,  
L-2985 Luxembourg,  
Tel. (352) 29 29 424 55, fax (352) 29 29 427 63.

---

**Renotification of a previously notified concentration****(Case COMP/M.2256 — Philips/Agilent Health Care Solutions)**

(2001/C 43/07)

**(Text with EEA relevance)**

1. On 22 December 2000 the Commission received notification of a proposed concentration pursuant to Article 4 of Council Regulation (EEC) No 4064/89<sup>(1)</sup>, as last amended by Regulation (EC) No 1310/97<sup>(2)</sup>, by which the Dutch undertaking Koninlijke Philips Electronics NV (Philips) acquires, within the meaning of Article 3(1)(b) of the Regulation, control of the medical business of the US undertaking Agilent Technologies Inc. (Agilent) by way of purchase of assets.

2. This notification was declared incomplete on 23 January 2001. The undertakings concerned have now provided the further information required. The notification became complete within the meaning of Article 10(1) of Regulation (EEC) No 4064/89 on 1 February 2001. Accordingly, the notification became effective on 1 February 2001.

3. The Commission invites interested third parties to submit their possible observations on the proposed operation.

Observations must reach the Commission not later than 10 days following the date of this publication. Observations can be sent by fax (No (32-2) 296 43 01 or 296 72 44) or by post, under reference COMP/M.2256 — Philips/Agilent Health Care Solutions, to:

European Commission,  
Directorate-General for Competition,  
Directorate B — Merger Task Force,  
Rue Joseph II/Jozef II-straat 70,  
B-1000 Brussels.

---

<sup>(1)</sup> OJ L 395, 30.12.1989, p. 1; corrigendum: OJ L 257, 21.9.1990, p. 13.

<sup>(2)</sup> OJ L 180, 9.7.1997, p. 1; corrigendum: OJ L 40, 13.2.1998, p. 17.

---